Foamix Obtains US Patent "Waterless Hydrophilic Foam" for Dermatological and Gynecological Drugs, Such as Antibiotics, Antifungals and Corticosteroids
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office.
Rehovot, Israel, April 27, 2012 --(PR.com)-- US Patent No. 8,114,385, entitled “Oleaginous pharmaceutical and cosmetic foam” covers a platform of versatile polyethylene glycol-based foam formulations, which can carry a variety of dermatological and gynecological drugs, such as antibiotics, antifungals, corticosteroids, anti-inflammatory, anti-acne and anti-rosacea drugs. This patent provides an exclusivity period until November 6, 2026.
This formulation platform is specifically important for drugs that degrade in the presence of water, and it enabled Foamix to formulate several water-sensitive drugs, including various corticosteroids (e.g., Fluocinolone Acetonide, Betamethasone Valerate, Betamethasone Dipropionate, Hydrocortisone Butyrate and Clobetasol Propionate) and vitamin D derivatives (e.g., Calcitriol and Calcipotriene).
"The grant of this US patent covering waterless hydrophilic foams is part of a broad platform of IP which continue to be developed by Foamix. Foamix now has 13 granted US patents, and about 60 applications in prosecution in the United States," remarks Dr. Dov Tamarkin, CEO of Foamix. "This current patent will now enable us to further develop an even wider range of products under patent protection, thereby adding value to us and to our partners.”
Waterless Hydrophilic Foam – an Innovative Foam Platform
The present invention provides stable foam compositions, which comprise primarily hydrophilic carriers, such as Polyethylene glycol. The claims cover the vehicle foam, as well as pharmaceutical compositions that contain at least one active agent for dermal and mucosal delivery. The composition is dispensed as foam providing a stable product that is pleasant and easy to spread, resulting in high patient compliance.
Foamix is the sole company that develops water free dermatological foams.
About Foamix
Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burn applications, as well as ophthalmic disorders. Foamix collaborates with leading pharmaceutical companies in the creation of advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio.
The Company’s development capabilities range from initial development of the formulations to scale-up, GMP manufacturing, preclinical and clinical studies.
Foamix has a strong in-house pipeline. The Company’s lead product, Topical Minocycline, is currently in Phase II clinical studies.
To date, Foamix has 13 issued patents in the United States, covering its foam and OilGel™ technology platforms. Additionally, the company has more than 150 patents and patent applications worldwide, of which about 60 applications are filed in the U.S.
For additional information please see www.foamix.co.il
Contact:
Dorit Hayon, Business Development Manager, Foamix Ltd., dorit@foamix.co.il
Dov Tamarkin, CEO, Foamix Ltd., dov@foamix.co.il.
This formulation platform is specifically important for drugs that degrade in the presence of water, and it enabled Foamix to formulate several water-sensitive drugs, including various corticosteroids (e.g., Fluocinolone Acetonide, Betamethasone Valerate, Betamethasone Dipropionate, Hydrocortisone Butyrate and Clobetasol Propionate) and vitamin D derivatives (e.g., Calcitriol and Calcipotriene).
"The grant of this US patent covering waterless hydrophilic foams is part of a broad platform of IP which continue to be developed by Foamix. Foamix now has 13 granted US patents, and about 60 applications in prosecution in the United States," remarks Dr. Dov Tamarkin, CEO of Foamix. "This current patent will now enable us to further develop an even wider range of products under patent protection, thereby adding value to us and to our partners.”
Waterless Hydrophilic Foam – an Innovative Foam Platform
The present invention provides stable foam compositions, which comprise primarily hydrophilic carriers, such as Polyethylene glycol. The claims cover the vehicle foam, as well as pharmaceutical compositions that contain at least one active agent for dermal and mucosal delivery. The composition is dispensed as foam providing a stable product that is pleasant and easy to spread, resulting in high patient compliance.
Foamix is the sole company that develops water free dermatological foams.
About Foamix
Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burn applications, as well as ophthalmic disorders. Foamix collaborates with leading pharmaceutical companies in the creation of advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio.
The Company’s development capabilities range from initial development of the formulations to scale-up, GMP manufacturing, preclinical and clinical studies.
Foamix has a strong in-house pipeline. The Company’s lead product, Topical Minocycline, is currently in Phase II clinical studies.
To date, Foamix has 13 issued patents in the United States, covering its foam and OilGel™ technology platforms. Additionally, the company has more than 150 patents and patent applications worldwide, of which about 60 applications are filed in the U.S.
For additional information please see www.foamix.co.il
Contact:
Dorit Hayon, Business Development Manager, Foamix Ltd., dorit@foamix.co.il
Dov Tamarkin, CEO, Foamix Ltd., dov@foamix.co.il.
Contact
Foamix Ltd
Dorit Hayon
97289316233
www.foamix.co.il
Dov Tamarkin, CEO, Foamix Ltd, +972-8-9316233 or dov@foamix.co.il.
Dorit Hayon
97289316233
www.foamix.co.il
Dov Tamarkin, CEO, Foamix Ltd, +972-8-9316233 or dov@foamix.co.il.
Contact
Categories